Company intelligence / Profile preview

Cyrano Therapeutics

Delray Beach, Florida, United Statescyranotherapeutics.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

Currently conducting a 32-week, randomized, double-blinded, placebo-controlled Phase 2 trial evaluating the safety and effectiveness of CYR-064 for hyposmia. A previous 92-patient pilot study showed success. Data readout from the current trial is expected in Q1 2025.

Therapeutic areas: Neurology
Modalities: Intranasal formulation
Industry: Biotech

Drug pipeline

1 asset

CYR-064

Unknown

Beyond the preview

Go deeper on Cyrano Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyrano Therapeutics.

Explore the full profile